tiprankstipranks
Trending News
More News >
Jack Nathan Medical Corp (TSE:JNH)
:JNH

Jack Nathan Medical (JNH) AI Stock Analysis

Compare
12 Followers

Top Page

TS

Jack Nathan Medical

(OTC:JNH)

Rating:34Underperform
Price Target:
Jack Nathan Medical faces substantial financial challenges, including negative profitability and high leverage, which severely impact its stock score. Technical indicators and valuation metrics further reinforce the cautious outlook, with weak price momentum and unattractive valuation measures.

Jack Nathan Medical (JNH) vs. iShares MSCI Canada ETF (EWC)

Jack Nathan Medical Business Overview & Revenue Model

Company DescriptionJack Nathan Medical (JNH) is a provider of primary care medical clinics and services, primarily operating within retail environments. The company focuses on delivering accessible healthcare solutions, co-locating its clinics within major retail partners to enhance convenience for patients. Jack Nathan Medical aims to improve healthcare accessibility and affordability by integrating medical services into everyday retail settings.
How the Company Makes MoneyJack Nathan Medical makes money through several key revenue streams. Primarily, the company generates revenue by offering medical services to patients in its clinics, which are often situated in high-traffic retail locations. These services include general practitioner consultations, preventative care, and minor medical procedures. Additionally, the company may receive funding from partnerships with retail chains, enabling them to establish clinics inside their stores. These partnerships help reduce overhead costs and provide a steady flow of potential patients due to the retail foot traffic. Furthermore, Jack Nathan Medical may leverage strategic alliances and collaborations with healthcare providers and insurers, enhancing service offerings and expanding patient reach, thus contributing to its revenue.

Jack Nathan Medical Financial Statement Overview

Summary
Jack Nathan Medical demonstrates revenue growth but faces significant challenges in profitability and liquidity. Persistent losses, negative equity, and substantial debt levels indicate high financial risk, while negative cash flows highlight potential sustainability issues.
Income Statement
35
Negative
The company has shown revenue growth, with a significant increase from 2023 to 2024. However, profitability remains a major concern as both gross and net profit margins are negative, indicating persistent losses. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and high expenses relative to revenue.
Balance Sheet
20
Very Negative
The balance sheet reveals a highly leveraged position with negative stockholders' equity, indicating financial instability. The debt-to-equity ratio is not applicable due to negative equity, and the equity ratio is also negative, highlighting a concerning level of liabilities compared to assets.
Cash Flow
30
Negative
The company is experiencing negative operating and free cash flows, which is a critical issue for sustainability. Although financing cash flow is positive, it primarily stems from high financing activities, which may not be sustainable in the long run. Operating cash flow to net income ratio is negative, suggesting cash flow challenges.
BreakdownTTMMar 2024Mar 2023Mar 2022Mar 2021Dec 2018
Income Statement
Total Revenue21.33M19.14M15.49M9.64M3.85M0.00
Gross Profit17.77M14.48M11.82M6.92M3.74M0.00
EBITDA-5.98M-4.96M-5.51M-7.54M-10.11M778.25K
Net Income-8.29M-6.64M-7.08M-7.81M-9.90M-18.09K
Balance Sheet
Total Assets6.66M11.19M6.45M10.65M406.78K84.20K
Cash, Cash Equivalents and Short-Term Investments365.22K3.07M1.46M7.69M406.78K84.20K
Total Debt13.87M12.39M4.55M713.02K713.02K0.00
Total Liabilities18.70M17.13M8.32M2.13M17.18K8.00K
Stockholders Equity-12.04M-5.95M-1.87M8.53M389.59K76.20K
Cash Flow
Free Cash Flow-5.13M-10.20M-4.59M-1.31M-566.27K-33.69K
Operating Cash Flow-6.94M-6.11M-2.00M-809.16K-66.53K-33.69K
Investing Cash Flow-2.05M-4.09M-2.69M-252.89K-252.89K0.00
Financing Cash Flow4.01M11.91M5.28M8.68M389.11K50.00K

Jack Nathan Medical Technical Analysis

Technical Analysis Sentiment
Negative
Last Price0.01
Price Trends
50DMA
0.01
Negative
100DMA
0.02
Negative
200DMA
0.02
Negative
Market Momentum
MACD
>-0.01
Negative
RSI
40.62
Neutral
STOCH
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For TSE:JNH, the sentiment is Negative. The current price of 0.01 is equal to the 20-day moving average (MA) of 0.01, below the 50-day MA of 0.01, and below the 200-day MA of 0.02, indicating a neutral trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 40.62 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for TSE:JNH.

Jack Nathan Medical Peers Comparison

Overall Rating
UnderperformOutperform
Sector (46)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
67
Neutral
C$1.08B30.45-3.53%17.19%-191.01%
46
Neutral
C$194.28M-4.22-8.60%2.64%13.54%-1.44%
TSPTX
38
Underperform
C$11.88M-42.50%31.86%
TSJNH
34
Underperform
C$413.49K111.59%22.44%-3.91%
* Healthcare Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
TSE:JNH
Jack Nathan Medical
0.01
-0.02
-66.67%
TSE:PTX
Platinex
0.10
-0.02
-16.67%
TSE:WELL
WELL Health Technologies Corp
4.25
-0.69
-13.97%

Jack Nathan Medical Corporate Events

Jack Nathan Health Reports Q3 Fiscal 2025 Results
Dec 30, 2024

Jack Nathan Health reported a 16% year-to-date revenue growth in its Q3 fiscal 2025 results, driven primarily by its expanding operations in Mexico. The company has completed the sale of its Canadian operations and is focusing on growing its Mexican clinics and exploring opportunities in the MedSpa sector.

Jack Nathan Health Sells Canadian Business for Growth
Dec 2, 2024

Jack Nathan Health has completed the sale of its Canadian business to WELL Health Technologies for Cdn$5 million, eliminating over Cdn$15 million in debt and streamlining its capital structure. The company will focus on its profitable Mexican operations, including clinics in Walmart locations, while securing future growth through a cash infusion from the asset sale.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 07, 2025